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The poultry disease coccidiosis, caused by infection with Eimeria spp. apicomplexan parasites, is
responsible for enormous economic losses to the global poultry industry. The rapid increase of
resistance to therapeutic agents, as well as the expense of vaccination with live attenuated vaccines,
requires the development of new effective treatments for coccidiosis. Because of their key regulatory
function in the eukaryotic cell cycle, cyclin-dependent kinases (CDKs) are prominent drug targets.
The Eimeria tenellaCDC2-related kinase 2 (EtCRK2) is a validated drug target that can be activated
in vitro by the CDK activator XlRINGO (Xenopus laevis rapid inducer of G2/M progression in
oocytes). Bioinformatics analyses revealed four putative E. tenella cyclins (EtCYCs) that are closely
related to cyclins found in the human apicomplexan parasite Plasmodium falciparum. EtCYC3a was
cloned, expressed in Escherichia coli and purified in a complex with EtCRK2. Using the non-
radioactive time-resolved fluorescence energy transfer (TR-FRET) assay, we demonstrated the
ability of EtCYC3a to activate EtCRK2 as shown previously for XlRINGO. The EtCRK2/EtCYC3a
complex was used for a combined in vitro and in silico high-throughput screening approach, which
resulted in three lead structures, a naphthoquinone, an 8-hydroxyquinoline and a 2-pyrimidinyl-
aminopiperidine-propane-2-ol. This constitutes a promising starting point for the subsequent lead
optimization phase and the development of novel anticoccidial drugs.
INTRODUCTION
The obligate intracellular apicomplexan parasites cause
devastating diseases in humans and domestic animals. Well-
known members of this phylum are Plasmodium falcipa-
rum, Toxoplasma gondii, Cryptosporidium parvum, Theileria
annulata and Eimeria tenella (Mehlhorn, 2008; Morrison,
2009). The poultry intestinal disease known as coccidiosis is
caused by Eimeria spp. such as Eimeria acervulina, Eimeria
necatrix, E. tenella and Eimeria mivati. The most pathogenic
species, E. tenella, provokes a haemorrhagic diarrhoea in
young chickens, leading to a loss of weight and appetite,
resorption problems, bacterial secondary infections and often
also to the bird’s death (Chauhan & Roy, 2007; Mehlhorn,
2008; Shirley et al., 2007). Moreover, coccidiosis causes
tremendous economic losses, in excess of three billion US
Dollars annually, to the world poultry industry (Dalloul &
Lillehoj, 2006; Shirley et al., 2007). Although prophylaxis
using live-attenuated vaccines is efficient, it may have
transitory adverse effects on chicken growth rate and is
economically restrictive due to the high costs of these vaccines
(Shirley & Bedrnı´k, 1997; Shirley, 2000; Shirley et al., 2005;
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Wallach et al., 2008). Several drugs are available for the
treatment of coccidiosis; however, resistance develops fre-
quently (Chapman, 1997; Williams et al., 1999). Therefore,
there is a clear need for new, affordable and effective anti-
coccidial drugs (Williams et al., 1999; Dalloul & Lillehoj,
2006; Shirley et al., 2007).
The apicomplexan life cycle involves both asexual (spor-
ogony and schizogony) and sexual (gamogony) reproduc-
tion (Mehlhorn, 2008). During schizogony the Eimeria
parasite proliferates asexually with a very high cell division
rate within the host cells (Kinnaird et al., 2004; Mehlhorn,
2008). Evidence for the presence of cyclin-dependent kin-
ases (CDKs) in apicomplexa (Doerig et al., 2000) including
Eimeria (Kinnaird et al., 2004) suggests a similar CDK-
dependent mode of cell cycle regulation to that found in
higher eukaryotes (Malumbres & Barbacid, 2009). There are
a high number of anti-cancer drugs that interfere with cell
cycle regulation, leading to the death of the rapidly dividing
cells (Tamamori et al., 1998; Doerig et al., 2002; Monaco &
Vallano, 2003; Malumbres & Barbacid, 2009). Therefore, we,
like others, predict that the disruption of the parasite’s cell
cycle will lead to its death (Engels et al., 2010; Waters &
Geyer, 2003).
CDKs play a key role in cell cycle progression, transcription
and neuronal function (Morgan, 1997), and are therefore
extremely interesting for the development of novel pharma-
ceuticals (Sielecki et al., 2000; Waters & Geyer, 2003; Bruno
et al., 1992; Schang et al., 2006). E. tenella CDC2-related
kinase 2 (EtCRK2) is by analogy assumed to play a similar
key role in Eimeria (Kinnaird et al., 2004; Engels et al., 2010).
It has been chemically validated using the synthetic flavone
flavopiridole, a specific CDK inhibitor (Dai & Grant, 2003).
Flavopiridole inhibits EtCRK2 in enzyme assays with an IC50
of 33±10 nM and a Ki of 11±3 nM, and fully inhibits E.
tenella schizont development at concentrations of 150 and
300 nM. Concentrations below 80 nm show no inhibitory
effects, and host cell toxicity is observed at concentrations
above 600 nM. Therefore, E. tenella CDKs are considered to
be chemically validated drug targets (Engels et al., 2010).
As the name implies, CDKs are dependent on activation
through binding of the respective cyclin (Olashaw &
Pledger, 2002). To the best of our knowledge, in contrast to
other apicomplexan parasites such as Plasmodium, no
eimerian cyclins have been reported so far.
Here, we describe the bioinformatic discovery of two
partial and two complete predicted cyclin-like proteins out
of the publicly available genome sequence of E. tenella. We
were able to clone one of the identified E. tenella cyclins
(EtCYCs) (EtCYC3a) and demonstrated that its protein
product was able to activate EtCRK2, in a similar manner to
that shown with the non-cyclin activator Xenopus laevis rapid
inducer of G2/M progression in oocytes (XlRINGO) (Engels
et al., 2010; Ferby et al., 1999). In a combined in vitro and in
silico high-throughput screening approach, using real (3514
compounds) and virtual (approx. 6 000 000 compounds)
compound libraries, we identified numerous hit compound
structures. The most promising hits were further analysed by
IC50 and Ki determinations, resulting in three lead structures.
The three lead structures have similar activities towards
EtCRK2/EtCYC3a and EtCRK2/XlRINGO. From our data
we conclude that most likely EtCYC3a is a natural activator
of EtCRK2.
METHODS
Bioinformatic analysis. Bioinformatic analyses were carried out in
analogy to Engels et al. (2010) and run on Silicon Graphics (SGI)
computers (models Origin 3200, O2, Octane2, Fuel) running the SGI
operating system IRIX6.5 as well as on Dell Precision workstations
(models 390 and T3400) running Red Hat Enterprise Linux 5 (RHEL
5). Publicly available E. tenella genome data were downloaded from
the Wellcome Trust Sanger Institute (http://www.sanger.ac.uk/
resources/downloads/protozoa/eimeria-tenella.html).
Chemoinformatic analysis. Chemoinformatic analyses were run
according to Engels et al. (2010). At the time of the analysis the virtual
compound library comprised approximately 66106 compounds.
Molecular docking was done using the docking software GOLD as
described in Engels et al. (2010). Molecular clustering was done using
the hierarchical clustering method of the software suite Spotfire
Decision Site 9.1.1 (Tibco Software) based on the MDL Keys (MDL
Information Systems; nowadays Accelrys).
Chemicals
Standard CDK inhibitors. The purity of all screening compounds
used was ¢90 %, if not stated otherwise. Flavopiridole was ordered as
flavopiridole hydrochloride hydrate from Sigma-Aldrich; IUPAC name
2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-
piperidinyl]-4H-1-benzopyran-4-one; purity ¢98 %. Indirubin-5-sul-
fonate was ordered from Biomol International; IUPAC name (3Z)-2-
oxo-3-(3-oxo-1H-indol-2-ylidene)-1H-indole-5-sulfonic acid; purity
¢98 %. 10-Z-Hymenialdisine was ordered from Axxora; IUPAC
name (4Z)-4-(2-amino-4-oxo-1H-imidazol-5-ylidene)-2-bromo-1,5,6,7-
tetrahydropyrrolo[2,3-c]azepin-8-one; purity ¢95 %. Purvalanol A was
ordered from Axxora; IUPAC name 2-[[6-[(3-chlorophenyl)amino]
-9-isopropyl-purin-2-yl]amino]-3-methyl-butan-1-ol; purity ¢95 %.
Staurosporine was ordered from Sigma-Aldrich; IUPAC name
(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-11-
(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:39,29,19-lm]pyrrolo
[3,4-j][1,7]benzodiazonin-1-one; purity ¢98 %. Alsterpaullone was
ordered from Axxora; IUPAC name 9-nitro-7,12-dihydro-5H-indolo
[3,2-d][1]benzazepin-6-one; purity¢95 %.
Novel identified inhibitors. BES124764 was ordered from Maybridge
Ltd; IUPAC name 1-phenylsulfanyl-3-[4-[[4-(trifluoromethyl)pyrimidin-
2-yl]amino]-1-piperidyl]propane-2-ol; purity ¢85 %. BES312351 was
ordered from Bridge Chem Pvt. Ltd., Mumbai, India; IUPAC name 7-
amino-8-hydroxy-quinoline-5-sulfonic acid hydrate; purity ¢95 %.
BES130131 was ordered from InterBioScreen Ltd, Chernogolovka,
Russia; IUPAC name 2,3-dichloro-5,8-dihydroxy-6-methyl-naphthalene-
1,4-dione; purity¢95 %. BES153950 was ordered from SPECS GmbH;
IUPAC name (4Z,5Z,6E)-4,5-bis(hydroxyimino)-6-phenacylidene-
hexahydropyrimidin-2-one; purity ¢90 %. BES154393 was ordered
from SPECS GmbH; IUPAC name 4-chloro-1H-pyrazolo[4,3-c]quinolin
-3-amine; purity¢90 %.
Biochemical analysis
Isolation of E. tenella sporozoites. Sporulated oocysts of E. tenella
Houghton strain (9.66105 oocysts ml21 in 4 % potassium dichromate
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solution) were used as the source of parasite material. Sporozoites were
obtained as described earlier (Hofmann & Raether, 1990). A 200 ml
volume of oocysts in potassium dichromate solution was centrifuged at
6 uC (2500 g, 3 min), resuspended in 100 ml sodium hypochlorite
(Honeywell Riedel-de Hae¨n) and stirred in this solution for no more
than 10 min until a deformation in the parasite cell wall was visible
(monitored by microscopy) (Hofmann & Raether, 1990). Following
centrifugation (2500 g, 3 min), floating oocysts were aspirated with a
vacuum pump, diluted in distilled water and again centrifuged (2500 g,
3 min) (Hofmann & Raether, 1990). This step was repeated several
times to remove the residual chloride. Oocysts were diluted in Hank’s
Balanced Salt Solution (HBSS; Adcock-Scientific) and fractured
by mixing with glass beads (1 mm diameter, Sigma-Aldrich) on a
vortex mixer until a disruption of 80 % of oocysts was detected
microscopically (Hofmann & Raether, 1990). The glass beads were
washed several times with buffer, and after centrifugation the sporocyst
pellet was resuspended in HBSS and stored at 4 uC (Hofmann &
Raether, 1990).
RNA isolation and cDNA production. The isolated sporocysts were
centrifuged in 2 ml Eppendorf tubes at 13 000 g for 10 min at 4 uC in
a tabletop centrifuge, and the pellets were collected. A 1 ml volume of
TRI Reagent (Invitrogen) was added to 100 mg of sporocysts and
placed on ice. The sample was immediately homogenized with a
Precellys 24 homogenizer (MO-BIO Laboratories), and the disruption
of sporocysts and sporozoites was verified microscopically. The total
RNA from sporozoites was prepared following the manufacturer’s
instructions.
In order to produce cDNA, RT-PCRs were performed with 10 mg of
total RNA using the SuperScript First-Strand Synthesis system for RT-
PCR (Invitrogen) according to the manufacturer’s instructions.
PCR amplification of EtCYC-like 3a (EtCYC3a) from cDNA. A full-
length EtCYC3a protein sequence was identified in silico by BLAST-
searching the E. tenella proteome with several known human and
protozoan cyclins. The Etcyc3a gene was amplified in vitro from 2 mg
E. tenella cDNA using Platinum Taq DNA Polymerase High Fidelity
(Invitrogen) in the presence of 2 mM MgSO4 and 150 pmol of each
primer (SRD, Oberursel, Germany). The primers contained BamHI
(forward primer, 59-TAGGATCCATGTTGGAGGCATCCCGAGAC-
39) or HindIII (reverse primer, 59-GGCAAGCTTAGCGCAGTGAT-
GGTTGTG-39) restriction sites (recognition sites underlined). The
reaction was incubated at 94 uC for 2 min, 40 cycles at 94 uC for 30s,
62 uC for 1 min and 68 uC for 1 min, followed by 10 min at 68 uC.
Amplified fragments were separated by agarose gel electrophoresis
and isolated using the QIAquick Gel Extraction kit (Qiagen)
following the manufacturer’s instructions.
After fragment isolation, the PCR product was digested with BamHI
and HindIII (both enzymes from Roche Diagnostics) prior to
insertion into the pMALc2X vector (New England Biolabs). The
resulting expression plasmid pMALc2X-Etcyc3a was amplified in
Escherichia coli TOP10 cells (Invitrogen) and the insert was verified
by sequencing. For protein expression, Escherichia coli BL21(DE3)
competent cells (Invitrogen) were transformed with the plasmid
pMALc2X-Etcyc3a.
Expression and purification of recombinant EtCRK2 and XlRINGO.
Recombinant EtCRK2 and XlRINGO were expressed and purified
according to Engels et al. (2010).
Expression and co-purification of recombinant EtCRK2-His/
maltose binding protein (MBP)-EtCYC3a complex. Both plasmids
(pQE60-Etcrk2 and pMALc2X-Etcyc3a) were transformed in
Escherichia coli BL21(DE3) (Invitrogen). The cells were used to
express the recombinant EtCRK2–His and MBP–EtCYC3a fusion
proteins separately overnight at 24 uC using 0.1 mM and 1 mM
IPTG, respectively. Cell pellets were harvested by centrifugation at
9000 g for 40 min. Pellets from both transformations [Escherichia coli
BL21(DE3) pLysS/pQE60-Etcrk2 and Escherichia coli BL21(DE3)/
pMALc2X-Etcyc3a] were pooled and disrupted together using a
French press. The cell lysate was incubated in a shaker for 1 h at
4 uC to allow for the formation of an EtCRK2–His/MBP-EtCYC3a
complex. The resulting complex was co-purified by amylose affinity
chromatography using the MBP-tag of EtCYC3a. Free MBP was
subsequently removed using size exclusion chromatography as
described for MBP–XlRINGO by Engels et al. (2010).
IC50, Ki determination, and compound solubility. IC50 and Ki deter-
mination based on the time-resolved fluorescence energy transfer
(TR-FRET) assay as well as compound solubility testing was done
according to Engels et al. (2010).
Liquid chromatography/mass spectrometry (LC/MS) and NMR
analyses for compound quality determination. LC/MS and NMR
analyses for compound quality control were conducted as described
in Engels et al. (2010).
RESULTS AND DISCUSSION
In silico identification of EtCYCs
In order to identify potential EtCYCs we ran a number of
BLAST database searches on the currently unfinished genomic
dataset of E. tenella using a wide set of cyclins, including
Plasmodium falciparum cyclin (PfCYC)1 (Le Roch et al.,
2000), PfCYC2, PfCYC3 and PfCYC4 (Merckx et al., 2003)
from P. falciparum, as query sequences in analogy to Engels
et al. (2010). The database queries revealed four potential E.
tenella gene sequences which might encode cyclins (Fig. 1a).
(1) Query sequence PfCYC1 identified a potentially homo-
logous gene product fragment of 141 aa, which we named
EtCYC1. It was not possible to identify the full-length
sequence of this hypothetical protein fragment.
(2) Query sequence PfCYC2 led to no results, i.e. no E.
tenella gene homologous to the corresponding Pfcyc2 gene
could be found.
(3) Query sequence PfCYC3 led to two significant hits,
which we named EtCYC3a and EtCYC3b. While the full-
length (358 aa) EtCYC3a sequence was available, only a
partial sequence for EtCYC3b (138 aa) could be retrieved.
The two sequences EtCYC3a and EtCYC3b share a distinct
sequence identity of 66 % at the protein level over the whole
available length of the EtCYC3b sequence. However, because
the available EtCYC3b sequence was only about one-third
the length of the corresponding EtCYC3a sequence and
because the N-terminal end as well as the C-terminal end of
the sequence were missing, we pursued our investigation
using the full-length sequence only. The molecular size of
the EtCYC3a protein was predicted to be 38 kDa.
(4) Query sequence PfCYC4 identified a full-length se-
quence (420 aa) which we named EtCYC4. The molecular
size of this potential protein was predicted to be 44 kDa.
The four hypothetical proteins and protein fragments
EtCYC1, EtCYC3a, EtCYC3b and EtCYC4 were subjected
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to an InterproScan analysis. A cyclin-box motif which
forms the first of five a-helical repeats of the canonical
cyclin fold (Jeffrey et al., 1995) was identified for each of
them (Fig. 1b). Other typical cyclin motifs such as the
MRAIL motif, the RXL motif and the destruction box
(Russo et al., 1996; Schulman et al., 1998; Morgan, 1997)
were not found in any of the hypothetical proteins.
PfCYC4 is unable to activate PfPK5 in vitro and has been
proposed to have roles distinct from cell cycle regulation
(Nairn & Greengard, 2001; Merckx et al., 2003). Although
PfCYC4 and EtCYC4 are homologous to each other, an
orthologous relation of the two proteins has not been
proven so far. Nevertheless, in the absence of other guides
to a decision, we discounted EtCYC4 from our analysis and
Fig. 1. Bioinformatic identification of cyclin-like proteins of E. tenella. (a) Multiple sequence alignment of the potential cyclin-like E.
tenella proteins (EtCYC1, EtCYC3a, EtCYC3b and EtCYC4). For EtCYC1 and EtCYC3b, only incomplete sequences could be
identified. Blue-shaded residues are conserved among the four sequences, yellow-shaded residues among any three of the four
sequences, grey-shaded residues among any two only. (b) Comparison of known cyclin-like sequences of P. falciparum and E.
tenella. The potential cyclin-like proteins are homologous to the known cyclin-like proteins of P. falciparum. The characteristic
cyclin box sequence motif is conserved among the apicomplexan cyclin-like protein sequences and is coloured blue.
HTS with the Eimeria tenella EtCRK2/EtCYC3a complex
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concentrated on EtCYC1 and EtCYC3a as being potential
activating partners of EtCRK2. As we were unable to access
full-length EtCYC1, we focused attention on EtCYC3a as
the potential activating partner of EtCRK2.
In vitro activation of EtCRK2
Activation of EtCRK2 by XlRINGO. XlRINGO is known to
be able to fully activate mammalian CDKs (Karaiskou et al.,
2001) as well as PfPK5 (Merckx et al., 2003; Nebreda 2006).
Therefore, we tested XlRINGO as an activator of EtCRK2.
Using a TR-FRET assay with a fluorescein-labelled histone
H1 substrate we determined the Km value for ATP to be
9.39±1.21 mM (data not shown) and its specific activity to
be 1.29±0.24 mmol min21 mg21 (Fig. 2a). From these data
we conclude that XlRINGO is able to activate EtCRK2.
Activation of EtCRK2 by EtCYC3a. To further study the
biochemical properties of EtCYC3a and its ability to
activate EtCRK2, we cloned the entire coding region into the
pMALc2X vector, allowing for the expression of an EtCYC3a–
MBP fusion protein (MBP–EtCYC3a) in Escherichia coli. Cells
expressing MBP–EtCYC3a and cells expressing EtCRK2–His
were pooled and disrupted together, and the cell lysate was
incubated to allow for the formation of an EtCRK2–His/
MBP–EtCYC3a complex. The resulting complex was co-
purified by amylase affinity chromatography using the MBP-
tag of EtCYC3a. If EtCRK2–His and MBP–EtCYC3a did
indeed form a stable complex, this affinity chromatography
step should have retained the protein complex as well as
monomeric MBP–EtCYC3a, while all other components not
having an MBP-tag should have been removed in the wash. A
gel electrophoresis under denaturing conditions (SDS-PAGE)
of the eluate fraction showed multiple proteins, including
two proteins at 32 and 80 kDa, corresponding to the sizes
expected for EtCRK2–His and MBP–EtCYC3a, respectively
(Fig. 3, lane 1, arrows). Size exclusion chromatography was
then performed and the 112 kDa complex purified (Fig. 3,
lane 2). Proteins between 60 and 80 kDa correspond most
likely to degradation products of MBP–EtCYC3a.
The purified EtCRK2–His/MBP–EtCYC3a (EtCRK2/EtCYC3a)
complex was active in the TR-FRET assay. EtCYC3a, like
XlRINGO, was able to fully activate EtCRK2 (Fig. 2a).
Moreover, both complexes showed comparable IC50 and Ki
values for standard inhibitors (Fig. 2b, Table 1). The Km
value for ATP of EtCRK2 in the EtCRK2/EtCYC3a complex
was 9.05±0.76 mM (n53) and is very similar to the Km
value for ATP of EtCRK2 in the EtCRK2/XlRINGO complex
(Table 2). However, its specific activity in the EtCRK2/
EtCYC3a complex of 0.15±0.02 mmol min21 mg21 is about
nine times lower than its specific activity of 1.29±0.24 mmol
min21 mg21 in the EtCRK2/XlRINGO complex (Table 2).
This is in good agreement with the findings of Merckx et al.
(2003) that XlRINGO is a stronger activator for PfPK5
than P. falciparum cyclins. We therefore hypothesize that
EtCYC3a is a natural activator of EtCRK2. Whether
EtCYC1, EtCYC3b and EtCYC4 are also able to activate
EtCRK2 has to be proven in future experiments.
Inhibition assays using EtCRK2 /XlRINGO and
EtCRK2/EtCYC3a complexes
In order to discover specific inhibitors of EtCRK2 we
performed an in vitro screening campaign supported by an
in silico hit enrichment (Fig. 4). In a primary screening we
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assayed approximately 3500 compounds from a highly
diverse excerpt of a vendor compound library on the active
EtCRK2/XlRINGO complex. The hit threshold for this
primary screen was set to 30 % inhibition at a concentration
of 30 mM, achieving a hit rate of 1.5 % (53 primary hits). The
primary hits were then confirmed in a secondary screen using
the EtCRK2/XlRINGO complex as well as the EtCRK2/
EtCYC3a complex, resulting in 23 compounds showing an
IC50 value equal to or below 100 mM (IC50 ¡100 mM) on
both EtCRK2 complexes. For the final confirmation step, the
23 compounds were freshly dissolved from solid stock
and tested on both EtCRK2 complexes (IC50¡100 mM), and
the structure of the compounds was verified using LC/MS
and NMR. The activity and the structural integrity of 14
compounds were verified.
In order to allow for the discovery of additional compounds
belonging to the same chemical classes we performed an in
silico hit enrichment. Each of the 14 actives was used as a
starting structure for a fingerprint-based similarity search
using a Tanimoto similarity metric and a scaffold-based
substructure search. The resulting virtual compound library
of 2208 compounds was then screened using molecular
docking and post processing as described by Engels et al.
(2010), leading to 64 potential inhibitors of EtCRK2. These
64 compounds were purchased and tested in our in vitro set-
up. Five compounds were confirmed to have an IC50 value
below 100 mM (IC50 ,100 mM) on both EtCRK2 com-
plexes. Together with the 14 hits coming from the initial in
vitro screen we found an overall hit set of 19 compounds.
In order to identify compound families whose members
belonged either to the same chemical class or to a common
scaffold with similar pharmacophore features we performed
a clustering based on the MDL Keys fingerprint. The
clustering identified three compound clusters: the naphtho-
quinone cluster, the 8-hydroxyquinoline cluster, and the 2-
pyrimidinyl-aminopiperidine-propane-2-ol cluster, which
we named after the most active representative of the
individual cluster. Naphthoquinones, 8-hydroxyquinolines
as well as 2-pyrimidinyl-aminopiperidine-propane-2-ols
(Table 3) have already been described in the literature as
inhibitors of different kinases (Aziz et al., 2008, Al-Sha’er &
Taha, 2010; Kim et al., 2011).
The most active representative of each of the three clusters
was subjected to Ki value and IC50 determinations on both
EtCRK2/XlRINGO and EtCRK2/EtCYC3a, as well as on the
complex of human CDK2 activated by human cyclin A:
HsCDK2/HsCYCA (Table 3). While the naphthoquinone
representative and the 8-hydroxyquinoline representative
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Fig. 3. SDS-PAGE of the co-purification of the EtCRK2–His/
MPB–EtCYC3a complex. Lane 1, amylase affinity chromato-
graphy, protein complex eluate fraction; lane 2, size exclusion
chromatography, eluate fraction above 100 kDa.
Table 1. Comparison of IC50 and Ki values of standard CDK inhibitors
Results are expressed as mean values±SD of at least three independent experiments (n53–6). See also Fig. 2(b).
CDK inhibitor IC50 (nM) Ki (nM)
EtCRK2/
XlRINGO
EtCRK2/
EtCYC3a
HsCDK2/
HsCYCA
EtCRK2/
XlRINGO
EtCRK2/
EtCYC3a
HsCDK2/
HsCYCA
Staurosporine 90±10 190±90 3±1 20±10 530±200 1±0
Indirubin-59-sulfonic acid 670±180 940±310 230±110 170±30 240±100 80±10
Purvalanol A 800±110 1030±180 140±40 80±10 360±130 40±1
Alsterpaullone 220±60 640±340 160±80 70±2 210±40 60±0
Flavopiridole 40±10 260±70 50±10 10±3 260±20 20±4
10-Z-Hymendialdisine 440±80 930±40 120±20 50±20 190±10 30±1
HTS with the Eimeria tenella EtCRK2/EtCYC3a complex
http://mic.sgmjournals.org 2267
displayed similar activities towards the EtCRK2 complexes
and HsCDK2/HsCYCA, BES124764, the 2-pyrimidinyl-
aminopiperidine-propane-2-ol representative, was appro-
ximately 25–30 times more active towards the two E.
tenella complexes than towards the HsCDK2/HsCYCA
complex. The Ki determination suggests ATP competitive-
ness, which in addition is backed by the molecular binding
mode found in docking experiments (Fig. 5). From its
molecular binding mode, BES124764 is an atypical kinase
inhibitor forming no H-bonds to the hinge region residues
(Fig. 5). Moreover, the selectivity site E88K reported by
Engels et al. (2010) is not addressed by this inhibitor, and it
is therefore not clear how the selectivity for the eimerian
enzyme is conferred. Therefore, we will focus future work
Table 2. Comparison of Km values and specific activity of EtCRK2 in the two protein–activator
complexes
Results are expressed as mean values±SD of at least three independent experiments (n53).
Parameter EtCRK2/XlRINGO EtCRK2/EtCYC3a
Specific activity (mmol min21 mg21) 1.29±0.24 0.15±0.02
Km for ATP (mM) 9.39±1.21 9.05±0.76
Km for fluorescein-labelled substrate (mM) 1.72±1.10 2.05±1.18
In vitro screening In silico hit enrichment
In silico vendor library
In silico structure searches
In silico docking and
post-processing
Compound selection
Actives
Actives
Actives
6 000 000
14
2208
199
64
5
5
Hit confirmation from
solid stock on
EtCRK2/XlRINGO and
EtCRK2/EtCYC3a
(IC50 ≤ 100 µM and
structure verification)
Compound library3 514
53
23
14
14
19
3
3
Lead cluster
Clustering on MDL Keys, remove single hits
Actives
Primary screen on
EtCRK2/XlRINGO
(inhibition ≥ 30 %)
Hit confirmation from
solid stock on
EtCRK2/XlRINGO and
EtCRK2/EtCYC3a
(IC50 ≤ 100 µM and
structure verification)
Hit verification on
EtCRK2/XlRINGO and
EtCRK2/EtCYC3a
(IC50 < 100 µM)
Fig. 4. Filtering steps during in vitro screening and in silico hit enrichment. Three lead compounds, each being the most active
representative of their respective cluster of structurally related compounds, were selected.
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towards the molecular mode of action of BES124764 and
its derivatives.
Conclusion
EtCRK2 is a valid drug target for the apicomplexan parasite
E. tenella (Engels et al., 2010). Although those authors were
able to assay EtCRK2 using the non-native activator
XlRINGO, the native activator of EtCRK2 was not known.
Therefore, one part of our work was devoted to the
identification of the putative native activator of EtCRK2.
Using bioinformatics and molecular biology methods we
successfully identified a number of potential cyclin-like
proteins which could be the native activators. The most
promising of these proteins, EtCYC3a, was studied further
and it was proven that it is able to activate EtCRK2.
Table 3. Comparison of IC50 and Ki values of the lead structures (most active representatives of the three clusters)
Results are expressed as mean values±SD of at least three independent experiments (n53–6).
Fig. 5. Top ranked docking solution for
BES124764. BES124764 is docked into the
predicted ATP binding pocket of EtCRK2.
Arene–H interactions to Gln84 and Ile10 and
the arene–arene interaction to Phe79 are
shown as dashed orange lines.
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In a subsequent in vitro screening on EtCRK2/XlRINGO
and EtCRK2/EtCYC3a supported by an in silico hit enrich-
ment, we were able to identify 19 active compounds. We
subsequently identified three clusters of structurally related
compounds, which we named after the most active repre-
sentative of the cluster as the naphthoquinone cluster,
8-hydroxyquinoline cluster and 2-pyrimidinyl-aminopiper-
idine-propane-2-ol cluster. The most active representative of
each of the three clusters was picked as a lead structure and
was assayed for its selectivity for EtCRK2 versus HsCDK2.
It turned out that BES124764, the representative of the
2-pyrimidinyl-aminopiperidine-propane-2-ol cluster, was
selective for EtCRK2. Therefore, BES124764 and derivatives
thereof will be introduced into lead optimization, the next
step of the stage-gated drug discovery process as described
by Rohwer et al. (2011). In the next steps of this process,
the compounds will be chemically modified and carefully
evaluated for their specificity against several CDK and CDK-
like proteins of mammalians, and for their activity towards
parasites in cell culture and in vivo.
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